ArticleChina CDC weekly2026
National and Regional Lifetime Risk of Developing and Dying from Lung Cancer - China, 2023.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer-related mortality in China. However, the lifetime risk (LTR) of lung cancer in China remains poorly understood. This study aimed to provide national and regional estimates of LTR of lung cancer in China in 2023. Methods: Lung cancer incidence and mortality data were sourced from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023. Population data were obtained from the China Statistical Yearbook and national census records. The lung cancer LTR was calculated using a standardized approach that accounts for multiple primary cancers. Results: In 2023, the LTR of developing lung cancer in China was 6.52% [95% uncertainty interval ( Conclusion: The estimated LTR of lung cancer in China is approximately one in 15 individuals and one in 17 deaths. The substantial regional variations in lung cancer risk highlight the need for targeted cancer control strategies and tailored healthcare planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.